Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.

Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P, Teo KK.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):463-71. doi: 10.1161/CIRCOUTCOMES.111.963637. Epub 2012 Jul 10.

2.

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Indian Polycap Study (TIPS)., Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N.

Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.

PMID:
19339045
3.

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.

Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, Neal B, Hillis GS, Rafter N, Tonkin A, Webster R, Billot L, Bompoint S, Burch C, Burke H, Hayman N, Molanus B, Reid CM, Shiel L, Togni S, Rodgers A; Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration..

Eur J Prev Cardiol. 2015 Jul;22(7):920-30. doi: 10.1177/2047487314530382. Epub 2014 Mar 27.

PMID:
24676715
4.

Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.

Patel A, Shah T, Shah G, Jha V, Ghosh C, Desai J, Khamar B, Chakraborty BS.

Am J Cardiovasc Drugs. 2010;10(2):95-103. doi: 10.2165/11532170-000000000-00000.

PMID:
20334446
5.

The evening versus morning polypill utilization study: the TEMPUS rationale and design.

Lafeber M, Grobbee DE, Bots ML, Thom S, Webster R, Rodgers A, Visseren FL, Spiering W.

Eur J Prev Cardiol. 2014 Apr;21(4):425-33. doi: 10.1177/2047487313476961. Epub 2013 Feb 4.

PMID:
23382539
6.

The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.

Xavier D, Pais P, Sigamani A, Pogue J, Afzal R, Yusuf S; Indian Polycap Study (TIPS) Investigators..

Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):96-7. doi: 10.1038/ncpcardio1438. Epub 2008 Dec 23. No abstract available.

PMID:
19104516
7.

Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.

Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Bompoint S, Billot L, Rodgers A; UMPIRE Collaborative Group..

JAMA. 2013 Sep 4;310(9):918-29. doi: 10.1001/jama.2013.277064. Erratum in: JAMA. 2013 Oct 9;310(14):1507. Naik, Nitish [added]; Reddy, Srinivas [added]; Balaji, Sham [corrected to Achuthan, Shyambalaji]; Damodra Rao, Modem [corrected to Damodra Rao, Kodem].

PMID:
24002278
8.

A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.

Carey KM, Comee MR, Donovan JL, Kanaan AO.

Ann Pharmacother. 2012 May;46(5):688-95. doi: 10.1345/aph.1Q621. Epub 2012 May 8. Review.

PMID:
22570437
9.

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.

Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC.

Am J Kidney Dis. 2005 Mar;45(3):473-84.

PMID:
15754269
11.

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.

Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD.

Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.

12.

Improving cardiovascular protection: focus on a cardiovascular polypill.

Barrios V, Escobar C.

Future Cardiol. 2016 Mar;12(2):181-96. doi: 10.2217/fca.15.80. Epub 2015 Dec 10. Review.

PMID:
26652213
13.

Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.

Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A.

BMJ. 2014 May 27;348:g3318. doi: 10.1136/bmj.g3318.

15.

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.

Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G; HOPE-3 Investigators..

N Engl J Med. 2016 May 26;374(21):2032-43. doi: 10.1056/NEJMoa1600177. Epub 2016 Apr 2.

16.

The Effect of a Cardiovascular Polypill Strategy on Pill Burden.

Truelove M, Patel A, Bompoint S, Brown A, Cass A, Hillis GS, Peiris D, Rafter N, Reid CM, Rodgers A, Tonkin A, Usherwood T, Webster R; Kanyini GAP Collaboration..

Cardiovasc Ther. 2015 Dec;33(6):347-52. doi: 10.1111/1755-5922.12151.

PMID:
26280247
17.

Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.

Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS.

Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2.

18.

Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.

Zomer E, Owen A, Magliano DJ, Ademi Z, Reid CM, Liew D.

Am J Cardiovasc Drugs. 2013 Apr;13(2):121-8. doi: 10.1007/s40256-013-0019-2.

PMID:
23532687
20.

Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact.

Bramlage P, Buhck H, Zemmrich C.

Clin Drug Investig. 2014 Apr;34(4):241-9. doi: 10.1007/s40261-014-0169-2.

PMID:
24482018

Supplemental Content

Support Center